Testosterone Enanthate Adolescent (12, 17) Dosing

When Adolescents Need Testosterone Enanthate

Testosterone enanthate is prescribed to adolescents in two distinct clinical scenarios: diagnosed hypogonadism and constitutional delay of growth and puberty (CDGP). The underlying cause determines both the dose and the duration of therapy, so accurate diagnosis before the first injection is non-negotiable.

Hypogonadism in adolescents falls into two categories. Hypergonadotropic hypogonadism (primary), seen in conditions like Klinefelter syndrome (47,XXY), involves testicular failure with elevated LH and FSH. Klinefelter syndrome affects approximately 1 in 660 males, making it the most common chromosomal cause of male hypogonadism [2]. Hypogonadotropic hypogonadism (secondary) results from pituitary or hypothalamic dysfunction, as in Kallmann syndrome or panhypopituitarism, and presents with low gonadotropins alongside low testosterone [1].

CDGP accounts for roughly 60% to 65% of adolescent males referred for pubertal delay [2]. These patients have a functional, intact hypothalamic-pituitary-gonadal axis that simply activates later than average. A short testosterone course can jump-start pubertal development while endogenous production catches up. The distinction matters: CDGP patients typically stop treatment after three to six months, while hypogonadal patients require lifelong replacement [2].

The 2018 Endocrine Society Clinical Practice Guideline recommends initiating testosterone therapy in boys with hypogonadism "at around 12 years of age" to mimic the normal timing of puberty, though the exact start depends on the patient's bone age and psychosocial readiness [1].

Starting Dose and Induction Protocol

The standard puberty induction protocol begins with testosterone enanthate 50 mg administered intramuscularly once every four weeks. This low starting dose replicates early pubertal testosterone levels (roughly 100 to 300 ng/dL) and allows for gradual virilization without prematurely accelerating bone maturation [1].

Every six to twelve months, the dose increases by approximately 50 mg per injection. A typical escalation looks like this:

• Months 0 to 12: 50 mg IM every 4 weeks
• Months 12 to 24: 100 mg IM every 4 weeks (or 50 mg every 2 weeks)
• Months 24 to 36: 150 mg IM every 2 weeks
• Months 36 and beyond: 100 to 200 mg IM every 2 weeks (adult maintenance)

The Endocrine Society guideline states that clinicians should "gradually increase the dose of testosterone over a period of time to achieve the adult replacement dose" and that "the rate of dose escalation should be guided by clinical response and serum testosterone levels" [1]. Adult maintenance typically targets trough serum testosterone between 400 and 700 ng/dL, measured 7 to 10 days after an injection in a biweekly protocol [1].

The induction phase generally spans 3 to 4 years, mirroring the natural progression of puberty from Tanner stage 2 through stage 5. Rushing this timeline with high initial doses risks rapid epiphyseal closure and compromised final adult height [4].

Dosing for Constitutional Delay of Growth and Puberty

CDGP requires a fundamentally different approach than permanent hypogonadism. The goal is a brief therapeutic nudge, not long-term replacement.

The most widely studied CDGP regimen uses testosterone enanthate 50 to 100 mg intramuscularly once monthly for three to six months [2]. Palmert and Dunkel's review in the New England Journal of Medicine noted that short courses of low-dose testosterone "accelerate growth velocity and the onset of secondary sexual characteristics without compromising final adult height" in CDGP [2].

After the treatment course ends, the clinician observes for 3 to 6 months. If the patient's own hypothalamic-pituitary-gonadal axis has activated (rising LH, FSH, and endogenous testosterone; testicular volume exceeding 4 mL), no further treatment is needed. If puberty stalls, a second short course or reclassification as hypogonadotropic hypogonadism may be warranted [2].

A practical clinical decision rule separates CDGP from true hypogonadism after an initial testosterone course:

• Testicular volume >4 mL at follow-up plus rising morning testosterone suggests CDGP. Observe.
• Testicular volume <4 mL after 6 months off therapy with persistently low gonadotropins suggests hypogonadotropic hypogonadism. Restart and plan for long-term replacement.
• Elevated gonadotropins with small testes suggests primary testicular failure. Karyotype if not already done.

Monitoring During Treatment

Safe adolescent testosterone therapy demands closer monitoring than adult TRT. Growth, bone maturation, hematologic parameters, and psychological well-being all require scheduled assessment.

Bone age radiographs should be obtained at baseline and every 6 to 12 months during induction [1]. The primary concern is premature epiphyseal fusion. If bone age advances more than 2 standard deviations ahead of chronological age, the prescriber should slow dose escalation or temporarily hold therapy. A 2018 Endocrine Society recommendation specifies monitoring bone age "to avoid compromising final adult height" [1].

Laboratory monitoring includes:

• Serum testosterone (trough): every 3 to 6 months during dose titration. Target mid-pubertal range initially (200 to 500 ng/dL), advancing toward adult range (400 to 700 ng/dL) over the induction period.
• LH and FSH: helps distinguish CDGP from permanent hypogonadism as treatment progresses.
• Complete blood count: testosterone stimulates erythropoiesis. Hematocrit exceeding 54% warrants dose reduction or phlebotomy [1]. In the Testosterone Trials (N=790 in the main cohort), hematocrit increases were the most common laboratory adverse finding, though that study enrolled men aged 65 and older [5].
• Liver function tests: while hepatotoxicity is associated with oral 17-alpha-alkylated androgens rather than injectable testosterone esters, baseline and periodic liver panels remain part of the standard monitoring protocol per the FDA prescribing information [4].

Growth velocity and Tanner staging should be recorded at each visit. A growth spurt of 8 to 12 cm per year is typical once mid-pubertal testosterone levels are achieved [2].

Psychological screening deserves attention at every follow-up. Adolescents with delayed puberty carry a documented higher risk of anxiety, depressive symptoms, and social withdrawal. The 2018 Endocrine Society guideline notes that "the psychological effects of delayed puberty can be significant and should be considered in the decision to initiate treatment" [1].

Injection Technique and Practical Considerations

Testosterone enanthate is formulated as an oil-based solution (typically in sesame oil or cottonseed oil) at a concentration of 200 mg/mL. For adolescent dosing, this means small injection volumes: 50 mg equals 0.25 mL.

The standard route is intramuscular injection into the gluteus medius (ventrogluteal site) or vastus lateralis using a 22- to 23-gauge, 1-inch to 1.5-inch needle [4]. Subcutaneous injection of testosterone enanthate is used off-label in some clinics, but the FDA-approved labeling specifies intramuscular administration [4].

Rotating injection sites reduces the risk of local reactions, which include pain, swelling, and oil-based nodule formation. For adolescents on monthly injections, the low frequency makes site rotation straightforward. Parents or guardians can be trained to administer home injections, though many pediatric endocrinologists prefer clinic-administered doses during the early induction period for closer oversight.

Storage is at controlled room temperature (20 to 25°C). The solution should be inspected visually before each injection. Crystallization can occur at lower temperatures but resolves with gentle warming.

Contraindications and Precautions in Adolescents

Testosterone enanthate carries specific contraindications outlined in the FDA prescribing information [4]. These include known or suspected breast carcinoma in males, known or suspected prostate carcinoma (rare but not absent in adolescents with genetic predisposition), and pregnancy or potential pregnancy in female contacts through transdermal transfer (not applicable to injections, but relevant for household counseling).

Precautions with particular relevance to adolescents:

• Sleep apnea: Testosterone can worsen obstructive sleep apnea. Obese adolescents with suspected sleep-disordered breathing should undergo evaluation before starting therapy [1].
• Polycythemia: Adolescents with cyanotic congenital heart disease or chronic hypoxic conditions face amplified erythrocytosis risk.
• Edema: Testosterone may cause sodium and water retention. This is rarely clinically significant in adolescents with normal cardiac and renal function, but it warrants awareness in patients with underlying conditions.
• Mood and behavior: While supraphysiologic testosterone doses are linked to aggression and mood instability, replacement-dose therapy targeting physiologic levels does not reliably produce these effects. The 2018 guideline found no evidence that physiologic testosterone replacement increases aggressive behavior in hypogonadal males [1].

Transitioning to Adult Maintenance

Once the adolescent reaches Tanner stage 5 and near-final adult height (bone age 15 to 17 years), the induction phase gives way to adult maintenance dosing. The standard adult regimen for testosterone enanthate is 100 to 200 mg intramuscularly every two weeks, or 50 to 100 mg weekly for more stable serum levels [1].

The transition should include a formal handoff from the pediatric endocrinologist to an adult endocrinologist or the patient's long-term managing physician. Dr. Shalender Bhasin, lead author of the 2018 Endocrine Society guideline, has emphasized that "the transition from pediatric to adult care is a vulnerable period during which treatment adherence often declines" [1]. Structured transition clinics, where pediatric and adult providers co-manage patients for 6 to 12 months, reduce gaps in care.

At the transition point, the following should be documented:

• Confirmed etiology of hypogonadism
• Total duration of testosterone therapy and cumulative dose history
• Most recent bone age and final height
• Baseline semen analysis if fertility counseling is relevant (exogenous testosterone suppresses spermatogenesis)
• Hematocrit trend over the treatment period

For patients with hypogonadotropic hypogonadism who desire future fertility, the adult provider may consider switching from testosterone to gonadotropin therapy (hCG with or without FSH) to induce spermatogenesis, a protocol described in the Endocrine Society guideline [1].

Off-Label Contexts and Emerging Considerations

The 2017 Endocrine Society guideline for gender-dysphoric persons addresses testosterone therapy for transgender male adolescents. The recommended approach begins with GnRH agonist suppression of endogenous puberty at Tanner stage 2 to 3, followed by gradual introduction of testosterone at approximately age 16, using the same induction protocol described for hypogonadal males [3]. This guideline specifies that "cross-sex hormone treatment should be prescribed and monitored by a pediatric endocrinologist or other clinician experienced in pubertal induction" [3].

Testosterone enanthate is also occasionally used off-label in adolescent females with specific conditions (certain disorders of sex development), but such use requires multidisciplinary team management and falls outside standard dosing guidelines for male hypogonadism.

Some clinicians have explored weekly subcutaneous microdosing protocols (25 to 50 mg weekly) in adolescents to reduce injection-day peaks and trough-related symptoms. Published evidence for this approach in the pediatric population remains limited, though adult data suggest more stable pharmacokinetics with weekly versus biweekly dosing [1].